Dexcom Loses Appeals Court Bid For AgaMatrix Lawsuit

Dexcom has reportedly lost its appeals court bid to reinitiate its patent dispute vs. AgaMatrix. Previously, Dexcom alleged that Agamatrix’s CGM technology infringed on Dexcom’s patents for improving sensor accuracy. Recall, AgaMatrix (and its subsidiary WaveForm) acquired CGM IP from iSense and Bayer in early 2016. Below, FENIX provides a brief overview of the litigation history between AgaMatrix and Dexcom as well as thoughts on potential resolutions.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.